Anakinra

8 March, 2021

An open label trial of anakinra to prevent respiratory failure in COVID-19

2024-03-29T14:13:13+03:00By hiss|Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: Anakinra, COVID-19, suPAR|

Evdoxia Kyriazopoulou, Periklis Panagopoulos, Symeon Metallidis, George N Dalekos, Garyphallia Poulakou, Nikolaos Gatselis, Eleni Karakike, Maria Saridaki, Georgia Loli, Aggelos Stefos, Danai Prasianaki, Sarah Georgiadou, Olga Tsachouridou, Vasileios Petrakis, Konstantinos Tsiakos, Maria Kosmidou, Vassiliki Lygoura, Maria Dareioti, Haralampos Milionis, Ilias C Papanikolaou, Karolina Akinosoglou, Dimitra-Melia Myrodia, Areti Gravvani, Aliki Stamou, Theologia Gkavogianni, Konstantina Katrini,

1 December, 2020

SAVE-MORE

2025-07-17T01:45:03+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early Management Of seveRE respiratory failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial Brief Description SAVE-MORE is a double-blind randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by

8 July, 2020

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

2024-03-29T13:31:59+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, COVID-19|

George Dimopoulos, Quirijn de Mast, Nikolaos Markou, Maria Theodorakopoulou, Apostolos Komnos, Maria Mouktaroudi, Mihai G Netea, Themistoklis Spyridopoulos, Rebecca J Verheggen, Jacobien Hoogerwerf, Alexandra Lachana, Frank L van de Veerdonk, Evangelos J. Giamarellos-Bourboulis Cell Host & Microbe 2020 Jul 8;28(1):117-123.e1 DOI 10.1016/j.chom.2020.05.007Download pdf 🡇 Funding The study was funded in part by the

1 April, 2020

SAVE

2024-10-18T12:29:07+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker

1 April, 2020

ESCAPE

2023-01-09T12:13:22+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous

1 December, 2017

PROVIDE

2024-10-18T11:36:45+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, Sepsis|

Completed study Official Study Title A Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis (PROVIDE) Brief Description PROVIDE is a randomized clinical trial aiming to the personalized therapy of patients at septic shock. Using biomarkers, enrolled patients are randomized through a double-dummy approach to immunotherapy or placebo

1 January, 2016

Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial

2023-02-16T15:33:15+03:00By hiss|Categories: Publications|Tags: Anakinra, clinical trial, Hidradenitis suppurativa, PhD|

Vassiliki Tzanetakou, Theodora Kanni, Sophia Giatrakou, Alexandros Katoulis, Evangelia Papadavid, Mihai G Netea, Charles A Dinarello, Jos W M van der Meer, Dimitrios Rigopoulos, Evangelos J. Giamarellos-Bourboulis JAMA Dermatology 2016 Jan;152(1):52-59 DOI: 10.1001/jamadermatol.2015.3903View article 🡇 Funding This study was supported in part by the Interleukin Foundation, by grant AI-15614 from the National Institutes

1 March, 2012

HIDRA03

2023-01-09T12:09:09+03:00By hiss|Categories: Completed, Interventional, Studies, Systemic inflammatory disorders|Tags: Anakinra, Hidradenitis suppurativa|

Completed study Official Study Title A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites: 2 sites in Greece Actual enrolment: 20 participants ClinicalTrials.gov Identifier: NCT01558375 EudraCT number: 2011-005145-12 National Organization for